479 related articles for article (PubMed ID: 30874905)
1. Role of Bisphosphonates in Breast Cancer Therapy.
Goldvaser H; Amir E
Curr Treat Options Oncol; 2019 Mar; 20(4):26. PubMed ID: 30874905
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
4. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
Gralow JR; Barlow WE; Paterson AHG; M'iao JL; Lew DL; Stopeck AT; Hayes DF; Hershman DL; Schubert MM; Clemons M; Van Poznak CH; Dees EC; Ingle JN; Falkson CI; Elias AD; Messino MJ; Margolis JH; Dakhil SR; Chew HK; Dammann KZ; Abrams JS; Livingston RB; Hortobagyi GN
J Natl Cancer Inst; 2020 Jul; 112(7):698-707. PubMed ID: 31693129
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
8. Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors.
Brufsky AM
Clin Breast Cancer; 2007 Dec; 8 Suppl 1():S22-34. PubMed ID: 18282367
[TBL] [Abstract][Full Text] [Related]
9. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis.
Mauri D; Valachis A; Polyzos IP; Polyzos NP; Kamposioras K; Pesce LL
Breast Cancer Res Treat; 2009 Aug; 116(3):433-9. PubMed ID: 19521766
[TBL] [Abstract][Full Text] [Related]
10. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.
Dhesy-Thind S; Fletcher GG; Blanchette PS; Clemons MJ; Dillmon MS; Frank ES; Gandhi S; Gupta R; Mates M; Moy B; Vandenberg T; Van Poznak CH
J Clin Oncol; 2017 Jun; 35(18):2062-2081. PubMed ID: 28618241
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet; 2015 Oct; 386(10001):1353-1361. PubMed ID: 26211824
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials.
Gnant M
Curr Cancer Drug Targets; 2009 Nov; 9(7):824-33. PubMed ID: 20025570
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
[TBL] [Abstract][Full Text] [Related]
14. Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future.
Kohno N
Int J Clin Oncol; 2008 Feb; 13(1):18-23. PubMed ID: 18307015
[TBL] [Abstract][Full Text] [Related]
15. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
Barrett-Lee P; Bloomfield D; Dougherty L; Harries M; Laing R; Patel H; Walker M
Curr Med Res Opin; 2007 Jul; 23(7):1575-82. PubMed ID: 17559749
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of the role of bisphosphonates in metastatic disease.
Ross JR; Saunders Y; Edmonds PM; Patel S; Wonderling D; Normand C; Broadley K
Health Technol Assess; 2004; 8(4):1-176. PubMed ID: 14960258
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
Hadji P; Coleman RE; Wilson C; Powles TJ; Clézardin P; Aapro M; Costa L; Body JJ; Markopoulos C; Santini D; Diel I; Di Leo A; Cameron D; Dodwell D; Smith I; Gnant M; Gray R; Harbeck N; Thurlimann B; Untch M; Cortes J; Martin M; Albert US; Conte PF; Ejlertsen B; Bergh J; Kaufmann M; Holen I
Ann Oncol; 2016 Mar; 27(3):379-90. PubMed ID: 26681681
[TBL] [Abstract][Full Text] [Related]
18. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study.
Kremer R; Gagnon B; Meguerditchian AN; Nadeau L; Mayo N
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25278509
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
20. The role of bisphosphonates in breast and prostate cancers.
Brown JE; Neville-Webbe H; Coleman RE
Endocr Relat Cancer; 2004 Jun; 11(2):207-24. PubMed ID: 15163299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]